—it would be that what Dr. Lam was referring to as the genomic signature of lung cancer, anything that has to do with genomics, with DNA testing or molecular testing, is done in pathology.
The first step is the diagnosis of lung cancer, which doesn't really require any of this genomic testing. However, we are now asked in pathology to subclassify lung cancers based on their genomic signature, on what type of biomarkers each tumour has that can either prognosticate the cancer's behaviour or predict the response to treatment. Those are predictive markers.
We currently do not test for any prognostic markers. We do test for the two, EGFR and ALK, which are predictive in regard to treatment response.